ArriVent BioPharma, Inc. (AVBP) Stock Forecast & Price Target

Compare

71 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AVBP Analyst Ratings

Strong Buy

11 Buy

0 Hold

0 Sell

Based on 11 analysts giving stock ratings to

ArriVent

BioPharma, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AVBP Stock 12 Month Forecast

Average Price Target

$41.33

▲(110.65% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for ArriVent BioPharma, Inc. in the last 3 months. The average price target is $41.33 with a high forecast of $47.00 and a low forecast of $31.00. The average price target represents a 110.65% change from the last price of $19.62.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","48":"$48","24.75":"$24.8","32.5":"$32.5","40.25":"$40.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$47.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$31.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,24.75,32.5,40.25,48],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.12,22.18769230769231,24.255384615384617,26.323076923076925,28.39076923076923,30.458461538461542,32.526153846153846,34.59384615384616,36.66153846153846,38.72923076923077,40.79692307692308,42.86461538461539,44.93230769230769,{"y":47,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.12,21.751538461538463,23.383076923076924,25.014615384615386,26.646153846153847,28.277692307692305,29.909230769230767,31.54076923076923,33.17230769230769,34.80384615384615,36.43538461538461,38.066923076923075,39.69846153846154,{"y":41.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.12,20.95692307692308,21.793846153846154,22.630769230769232,23.46769230769231,24.304615384615385,25.141538461538463,25.978461538461538,26.815384615384616,27.652307692307694,28.48923076923077,29.326153846153847,30.163076923076922,{"y":31,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.5,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.73,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.78,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.64,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.89,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.73,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.52,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.12,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$47.00

Average Price Target$41.33

Lowest Price Target$31.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Sam Slutsky

LifeSci Capital

$36

Buy

83.49%

Upside

Reiterated

01/11/26

ArriVent Buy Rating: Favorable Risk‑Reward on Firmonertinib Ahead of Pivotal FURVENT Phase 3 Readout

Michael Schmidt

Guggenheim

$45

Buy

129.36%

Upside

Reiterated

01/08/26

Guggenheim Sticks to Their Buy Rating for ArriVent BioPharma, Inc. (AVBP)

Unknown Analyst

Oppenheimer

Not Ranked

Oppenheimer

$44

Buy

124.26%

Upside

Reiterated

01/06/26

Oppenheimer Sticks to Their Buy Rating for ArriVent BioPharma, Inc. (AVBP)

Justin Zelin

BTIG

$45

Buy

129.36%

Upside

Reiterated

01/02/26

ArriVent BioPharma, Inc. (AVBP) Receives a Buy from BTIG

Li Watsek

Cantor Fitzgerald

Buy

―

Initiated

12/22/25

ArriVent Biopharma initiated with an Overweight at Cantor FitzgeraldArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald

Asthika Goonewardene

Truist Financial

Buy

―

Reiterated

12/08/25

Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (NASDAQ: AVBP), CG Oncology, Inc. (NASDAQ: CGON) and Disc Medicine (NASDAQ: IRON)

Mayank Mamtani

B. Riley Securities

$37

Buy

88.58%

Upside

Reiterated

12/04/25

Robert Burns

H.C. Wainwright

$42

Buy

114.07%

Upside

Reiterated

11/11/25

H.C. Wainwright Keeps Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)

Yigal Nochomovitz

Citi

$33→$31

Buy

58.00%

Upside

Reiterated

11/11/25

ArriVent Biopharma price target lowered to $31 from $33 at CitiArriVent Biopharma price target lowered to $31 from $33 at Citi

Kaveri Pohlman

Clear Street

$32→$47

Buy

139.55%

Upside

Reiterated

11/11/25

ArriVent Biopharma price target raised to $47 from $32 at Clear StreetArriVent Biopharma price target raised to $47 from $32 at Clear Street

Soumit Roy

JonesTrading

$45

Buy

129.36%

Upside

Reiterated

11/11/25

ArriVent BioPharma, Inc.: Strategic Advancements and Promising Developments Drive Buy Rating with $45 Price Target

Kalpit Patel

Wolfe Research

$37

Buy

88.58%

Upside

Reiterated

07/21/25

ArriVent BioPharma, Inc. (AVBP) Receives a Buy from B.Riley Financial

Corinne Johnson

Goldman Sachs

Buy

―

Reiterated

07/18/25

We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Sam Slutsky

LifeSci Capital

$36

Buy

83.49%

Upside

Reiterated

01/11/26

ArriVent Buy Rating: Favorable Risk‑Reward on Firmonertinib Ahead of Pivotal FURVENT Phase 3 Readout

Michael Schmidt

Guggenheim

$45

Buy

129.36%

Upside

Reiterated

01/08/26

Guggenheim Sticks to Their Buy Rating for ArriVent BioPharma, Inc. (AVBP)

Unknown Analyst

Oppenheimer

Not Ranked

Oppenheimer

$44

Buy

124.26%

Upside

Reiterated

01/06/26

Oppenheimer Sticks to Their Buy Rating for ArriVent BioPharma, Inc. (AVBP)

Justin Zelin

BTIG

$45

Buy

129.36%

Upside

Reiterated

01/02/26

ArriVent BioPharma, Inc. (AVBP) Receives a Buy from BTIG

Li Watsek

Cantor Fitzgerald

Buy

―

Initiated

12/22/25

ArriVent Biopharma initiated with an Overweight at Cantor FitzgeraldArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald

Asthika Goonewardene

Truist Financial

Buy

―

Reiterated

12/08/25

Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (NASDAQ: AVBP), CG Oncology, Inc. (NASDAQ: CGON) and Disc Medicine (NASDAQ: IRON)

Mayank Mamtani

B. Riley Securities

$37

Buy

88.58%

Upside

Reiterated

12/04/25

Robert Burns

H.C. Wainwright

$42

Buy

114.07%

Upside

Reiterated

11/11/25

H.C. Wainwright Keeps Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)

Yigal Nochomovitz

Citi

$33→$31

Buy

58.00%

Upside

Reiterated

11/11/25

ArriVent Biopharma price target lowered to $31 from $33 at CitiArriVent Biopharma price target lowered to $31 from $33 at Citi

Kaveri Pohlman

Clear Street

$32→$47

Buy

139.55%

Upside

Reiterated

11/11/25

ArriVent Biopharma price target raised to $47 from $32 at Clear StreetArriVent Biopharma price target raised to $47 from $32 at Clear Street

Soumit Roy

JonesTrading

$45

Buy

129.36%

Upside

Reiterated

11/11/25

ArriVent BioPharma, Inc.: Strategic Advancements and Promising Developments Drive Buy Rating with $45 Price Target

Kalpit Patel

Wolfe Research

$37

Buy

88.58%

Upside

Reiterated

07/21/25

ArriVent BioPharma, Inc. (AVBP) Receives a Buy from B.Riley Financial

Corinne Johnson

Goldman Sachs

Buy

―

Reiterated

07/18/25

We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ArriVent BioPharma, Inc.

3 Months

xxx

Success Rate

8/13 ratings generated profit

Average Return

+7.20%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +7.20% per trade.

1 Year

Soumit RoyJonesTrading

Success Rate

3/5 ratings generated profit

Average Return

-2.40%

reiterated a buy rating 2 months ago

Copying Soumit Roy's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of -2.40% per trade.

2 Years

xxx

Success Rate

3/5 ratings generated profit

Average Return

-2.40%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of -2.40% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AVBP Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AVBP has received 17 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. AVBP average Analyst price target in the past 3 months is 41.33.

Each month's total comprises the sum of three months' worth of ratings.

AVBP Financial Forecast

AVBP Earnings Forecast

Next quarter’s earnings estimate for AVBP is -$0.87 with a range of -$0.92 to -$0.80. The previous quarter’s EPS was -$0.83. AVBP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year AVBP has Performed in-line its overall industry.

No data currently available

AVBP Sales Forecast

Next quarter’s sales forecast for AVBP is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AVBP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AVBP has Performed in-line its overall industry.

AVBP Stock Forecast FAQ

What is AVBP’s average 12-month price target, according to analysts?

Based on analyst ratings, ArriVent BioPharma, Inc.’s 12-month average price target is 41.33.

What is AVBP’s upside potential, based on the analysts’ average price target?

ArriVent BioPharma, Inc. has 110.65% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AVBP a Buy, Sell or Hold?

ArriVent BioPharma, Inc. has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.

What is ArriVent BioPharma, Inc.’s price target?

The average price target for ArriVent BioPharma, Inc. is 41.33. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $47.00 ,the lowest forecast is $31.00. The average price target represents 110.65% Increase from the current price of $19.62.

What do analysts say about ArriVent BioPharma, Inc.?

ArriVent BioPharma, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of AVBP?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

ArriVent BioPharma, Inc. (AVBP) Stock Forecast & Price Target

AVBP Analyst Ratings

AVBP Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering ArriVent BioPharma, Inc.

AVBP Analyst Recommendation Trends

AVBP Financial Forecast

AVBP Earnings Forecast

AVBP Sales Forecast

AVBP Stock Forecast FAQ

Detailed List of Analyst Forecasts